Publication
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerMelanomacivic_curation1.00
- drugCapivasertibcivic_curation1.00
- drugPI3K/BET Inhibitor LY294002civic_curation1.00
- geneMTORcivic_curation1.00
- variantMTOR H1968Ycivic_curation1.00
- variantMTOR Mutationcivic_curation1.00
- variantMTOR P2213Scivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26490311
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MTOR H1968Y2 | ||||||||
| Capivasertib | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | rejected | EID721In a cell line with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth. PMID 26490311 · Kong et al., 2016 · Open in CIViC | civic |
| Capivasertib + PI3K/BET Inhibitor LY294002Substitutes | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID713In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth. PMID 26490311 · Kong et al., 2016 · Open in CIViC | civic |
| MTOR Mutation1 | ||||||||
| (prognostic) | Melanoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID712Median overall survival of patients with nonsynonymous mutations in mTOR was shorter. PMID 26490311 · Kong et al., 2016 · Open in CIViC | civic |
| MTOR P2213S1 | ||||||||
| Capivasertib + PI3K/BET Inhibitor LY294002Combination | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID722In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth. PMID 26490311 · Kong et al., 2016 · Open in CIViC | civic |